| Nov 1 |
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
|
| Oct 23 |
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
|
| Oct 23 |
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
|
| Oct 10 |
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
|
| Oct 8 |
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
|
| Sep 23 |
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
|
| Sep 12 |
CNS Pharmaceuticals regains Nasdaq compliance
|
| Sep 12 |
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
|
| Sep 4 |
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 3 |
IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
|
